10-Q: Tilray Brands Swings to Profit, Boosts Cash Flow

Tilray Brands, Inc. reported a significant swing to net income and improved cash flow from operations and investing activities for the quarter ended August 31, 2025, despite slight revenue growth and declining gross margins in key segments.

Summary

• Net income reached $1.5 million for the three months ended August 31, 2025, a substantial improvement from a $34.7 million net loss in the prior year period.
• Operating income was $2.1 million, reversing an operating loss of $36.6 million in the previous year.
• Net revenue increased by 5% to $209.5 million, up from $200.0 million in the prior year.
• Adjusted EBITDA grew by 9% to $10.2 million, compared to $9.3 million in the prior year.
• Cash and cash equivalents increased to $264.8 million as of August 31, 2025, from $221.7 million at May 31, 2025.
• Cash used in operating activities significantly reduced to $1.3 million from $35.3 million in the prior year.
• Cash provided by investing activities turned positive at $24.5 million, compared to $49.4 million used in the prior year.
• Operating expenses decreased by 42% to $55.4 million, primarily due to lower amortization, a $15.0 million gain from contingent consideration fair value change, and reduced restructuring and litigation costs.
• Gross profit decreased by 4% to $57.5 million, with overall gross margin declining to 27% from 30%.

Sentiment

Score: 7

Explanation: The company demonstrated a significant financial turnaround, moving from a substantial net loss to a profit and improving cash flows. Operating expenses were effectively managed, and strategic initiatives like Project 420 are yielding savings. However, declining gross margins in key segments, ongoing market price compression, and delays in international permits present headwinds. The capital raise activities and strategic acquisitions indicate a proactive management approach, but the overall market environment remains challenging.

Positives

• Achieved net income of $1.5 million, a significant turnaround from a $34.7 million net loss in the prior year.
• Operating income improved substantially to $2.1 million from a $36.6 million operating loss.
• Adjusted EBITDA increased by 9% to $10.2 million, indicating improved operational efficiency.
• Cash flow from operating activities improved dramatically, reducing cash usage from $35.3 million to $1.3 million.
• Cash flow from investing activities turned positive, providing $24.5 million compared to using $49.4 million in the prior year.
• Total operating expenses decreased by 42% ($40.9 million reduction), driven by lower amortization, a $15.0 million gain from contingent consideration, and reduced restructuring and litigation costs.
• Cannabis segment net revenue increased by 5% to $64.5 million, with Canadian adult-use cannabis revenue growing 12% to $64.1 million.
• International cannabis revenue grew by 10% to $13.4 million.
• Distribution segment net revenue increased by 9% to $74.0 million.
• Wellness segment net revenue increased by 3% to $15.2 million.
• Successfully reduced long-term debt to $144.2 million and convertible debentures payable to $84.3 million.
• Achieved $25.1 million in synergy savings from Project 420 initiatives to date, with completion expected in Q3 fiscal 2026.

Negatives

• Gross profit decreased by 4% to $57.5 million, and overall gross margin declined to 27% from 30%.
• Beverage segment net revenue slightly decreased by 0% to $55.7 million, with gross margin declining to 38% from 41%.
• Cannabis segment gross margin decreased to 36% from 40%, attributed to increased participation in lower-margin product categories in the Canadian adult-use market.
• Distribution segment gross margin decreased to 11% from 12% due to a change in product mix.
• Wholesale cannabis revenue decreased by 25% to $4.2 million due to strategic redirection of volume to other markets.
• Warrant liability increased to $4.8 million from $1.1 million, resulting in a $3.7 million loss on change in fair value.
• Foreign exchange gain decreased significantly to $6.9 million from $11.9 million in the prior year.
• Ongoing price compression in specific Canadian cannabis categories, intensified by fierce competition among approximately 1,000 Licensed Producers.
• Experienced extensive delays in receipt of import/export permits for international medical cannabis shipments.

Risks

• May not achieve the expected revenue or other benefits from the craft beer operations acquired in fiscal years 2024 and 2025.
• May experience difficulties integrating operations and realizing the expected benefits of recent acquisitions, including the Craft brands acquisitions.
• The cannabis business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations, and timely renewals.
• Government regulation is evolving, including potential regulatory developments in the United States to reschedule cannabis from Schedule I to Schedule III or revise the current federal framework for hemp-derived cannabis, as well as uncertainties and potential delays in receiving required export/import permits in Europe and Australia.
• Faces intense competition, including from the illicit cannabis market, and anticipates competition will increase, which could hurt the business.
• Production and processing facilities are integral to the business, and adverse changes or developments affecting facilities may have an adverse impact.
• Regulations constrain the ability to market and distribute products in Canada.
• United States regulations relating to hemp-derived CBD products, Delta-9 products, and medical cannabis products are new and rapidly evolving, and changes may not develop in the timeframe or manner most favorable to business objectives.
• Changes in consumer preferences or public attitudes about alcohol could decrease demand for beverage products.
• SweetWater, Breckenridge, Montauk, and recently-acquired craft beer brands each face substantial competition in the beer industry or the broader market for beverage products.
• Subject to litigation, arbitration, and demands, which could result in significant liability and costs, and impact resources and reputation.
• Business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures.
• Additional impairments of goodwill and impairments of long-lived assets could have a material adverse impact on financial results.
• Has a limited operating history and a history of net losses, and may not achieve or maintain profitability in the future.
• Strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose the company to risks.
• May not be able to successfully identify and execute future acquisitions, dispositions, or other equity transactions or to successfully manage their impacts.
• Subject to risks inherent in an agricultural business, including the risk of crop failure.
• Depends on recurring customers for a substantial portion of revenue; failure to retain or expand customer relationships or reduced purchases could significantly decline revenue.
• Products may be subject to recalls for a variety of reasons, which could require significant management and capital resources.
• Significant interruptions in access to certain supply chains for key inputs may impair operations.
• Management may not be able to successfully establish and maintain effective internal controls over financial reporting.
• The price of common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.
• May not have the ability to raise the funds necessary to settle conversions of convertible securities in cash or to repurchase convertible securities upon a fundamental change.
• Cryptocurrency strategy faces high risk and uncertainty in light of market volatility and an evolving regulatory landscape.

Future Outlook

Tilray Brands expects to continue leveraging its brands, infrastructure, expertise, and capabilities to drive revenue growth, achieve industry-leading profitability, and build sustainable shareholder value. The company is focused on developing strong data analytics and consumer insights, category management leadership, and assessing opportunities for new categories, products, and geographies. Management anticipates continued price compression in the Canadian cannabis market but aims to mitigate impacts through cost savings and strategic redirection of inventory to higher-margin international markets. The company expects cannabis legalization to gain traction in Europe, albeit slowly, and aims to complete its Project 420 synergy optimization plan in the third quarter of fiscal 2026.

Management Comments

• Our overall strategy is to leverage our brands, infrastructure, expertise and capabilities to drive revenue growth in the industries in which we compete, achieve industry-leading profitability and build sustainable, long-term shareholder value.
• We continue to focus on developing strong capabilities in data analytics and consumer insights, drive category management leadership and assess opportunities for the introduction of new categories, products and entries into new geographies.
• We are relentlessly focused on managing our cost structure and expenses in order to maintain our strong financial position.
• Tilray continued to lead the Canadian market with the highest cannabis revenue in Canada.
• We continue to opportunistically redirect certain inventories to international cannabis markets, which is expected to generate higher margin sales.
• We believe that Tilray remains uniquely positioned to maintain and gain significant market share in the markets in which we participate.
• We expect to complete the synergy optimization plan in the third quarter of fiscal 2026.
• We intend to use the net proceeds from the ATM Program to fund strategic and accretive acquisitions or investments in businesses and capital expenditures for acquired businesses, including potential acquisitions of assets to capitalize on expected regulatory advancements or expansion opportunities.
• We are committed to optimizing our capital structure and enhancing financial flexibility as we intend to continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their underlying maturity date in June 2027, subject to market conditions.

Industry Context

The filing highlights an evolving Canadian cannabis market with persistent price compression and intense competition among numerous licensed producers, driving Tilray to focus on cost savings and higher-margin international sales. In Europe, medical cannabis legalization is progressing slowly across multiple countries, with Germany remaining the largest market, and some countries exploring adult-use legalization. Tilray is leveraging its vertically integrated infrastructure and EU-GMP facilities to capitalize on international growth. The craft beer segment faces declining growth and distributor consolidation, prompting Tilray's Project 420 initiatives for portfolio optimization and synergy realization. The wellness market continues to grow, with Tilray focusing on value-added innovations in natural and organic food and beverages.

Comparison to Industry Standards

• Tilray continued to lead the Canadian market with the highest cannabis revenue in Canada and experienced a marginal increase in market share in Canada from 9.3% to 9.4% from the immediately preceding quarter, as reported by Hifyre data for all provinces (excluding Quebec where Weedcrawler was deemed more accurate).
• Breckenridge Distillery's Double Gold awards at prestigious competitions, including Breckenridge Reserve Port Cask Finish being named the World's best finished Bourbon at the 2024 World Whiskies Awards, underscore strong product quality and recognition within the spirits industry.
• The Canadian cannabis industry has experienced a reduction in excess inventory resulting in price increases in the B2B market due to a transition by many licensed producers to asset-light business models, indicating Tilray is navigating a changing competitive landscape.
• Tilray is one of only three manufacturers of medical cannabis in Germany and a leading supplier of medical cannabis in Poland, demonstrating a strong competitive standing in key European medical cannabis markets.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing legal proceedings and disputes in the ordinary course of business.
• Total estimated litigation expense accrual included in accrued liabilities was $12.0 million as of August 31, 2025, down from $12.4 million as of May 31, 2025.
• Management believes appropriate legal reserves have been established and that incremental liabilities are not expected to have a material adverse effect, though ultimate resolution could be material.
• No material changes in legal proceedings since the Annual Report on Form 10-K for May 31, 2025.

Related Party Transactions

• Tilray acquired a promissory note in the amount of $14,821,356 from Double Diamond Holdings Ltd. (DDH), payable by Aphria Diamond Inc. (a 51% owned subsidiary of Tilray).
• As consideration for the note, Tilray issued 8,617,068 shares of its Common Stock to DDH.
• DDH is a joint venturer with Aphria Inc. (Tilray's wholly-owned subsidiary) in Aphria Diamond.
• DDH's management team provides additional services to Tilray at no incremental cost, including expert advice on vegetable cultivation, cannabis yields for Quebec and Cayuga facilities, and cannabis cultivation insights for the Portugal facility.

Stakeholder Impact

• Shareholders: Potential dilution from ATM program and share issuance for promissory note; potential for increased shareholder value from improved financial performance and strategic initiatives; exposure to stock price volatility.
• Employees: Restructuring costs include employee termination severance and benefits related to reorganization; stock-based compensation is a component of employee remuneration; CEO's compensation benefits were amended.
• Customers: Impacted by portfolio optimization (SKU rationalization), new product innovations (Hemp Derived Delta-9, non-alcoholic beverages, etc.), and changes in distribution networks.
• Creditors: Long-term debt and convertible debentures are being managed, with opportunistic repurchases of convertible notes planned; new financial covenants for ABC Group's revolving credit facility.
• Suppliers: Potential impact from supply chain disruptions and tariffs on input materials.

Next Steps

• Complete the Project 420 synergy optimization plan in the third quarter of fiscal 2026.
• Continue to manage SKU performance within the beverage portfolio on a one in and one out basis to maximize SKU productivity.
• Continue to evaluate the wholesale cannabis market and opportunistically sell where it makes sense.
• Continue to invest in marketing, promotion, and infrastructure for recently acquired beverage brands.
• Continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their maturity date in June 2027.
• Evaluate the effect of adopting new accounting pronouncements (ASU 2023-05, ASU 2023-06, ASU 2023-09, ASU 2024-03).
• Complete the sale of the Fort Collins, CO partially vacant warehouse facility during the fiscal year ended May 31, 2026.
• Continue to review and integrate internal control structures of recently acquired Craft Acquisition II businesses.

Key Dates

Recommendation

Tilray Brands demonstrated a significant financial turnaround, achieving net income and positive cash flow from investing activities, alongside a substantial reduction in operating expenses. This indicates improved operational efficiency and strategic execution. However, the company faces persistent challenges including declining gross margins in key segments, ongoing price compression in the Canadian cannabis market, and delays in international permits. While management is actively pursuing cost savings and portfolio optimization, the mixed financial signals and inherent industry volatility suggest a 'hold' position. Investors should monitor the successful integration of acquisitions, the realization of Project 420 synergies, and the impact of evolving regulatory landscapes on gross margins and revenue growth.

Keywords

Cannabis, Beverage, Wellness, Distribution, Tilray Brands, SEC Filing, 10-Q, Financial Results, Craft Beer, Medical Cannabis, Adult-Use Cannabis, Adjusted EBITDA, Project 420, Acquisitions, Regulatory Risk, Market Share, Liquidity, Capital Structure, Promissory Note, Warrants, Stock-based Compensation